Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Phase of Trial: Phase I

Latest Information Update: 06 Apr 2019

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Adenoid cystic carcinoma; B-cell lymphoma; Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lymphoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Apr 2019 Results (n=22) of expansion cohort of patients with advanced or metastatic adenoid cystic carcinoma published in the Investigational New Drugs
    • 12 Sep 2018 Results published in the European Journal of Cancer.
    • 06 Aug 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top